Cargando…
Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats
Dao-Chi powder (DCP) has been widely used in the treatment of inflammatory diseases in the clinical practice of traditional Chinese medicine, but has not been used in acute pancreatitis (AP). This study aimed to evaluate the effect of DCP on severe AP (SAP) and SAP-associated intestinal and cardiac...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310041/ https://www.ncbi.nlm.nih.gov/pubmed/35899121 http://dx.doi.org/10.3389/fphar.2022.922130 |
_version_ | 1784753305918898176 |
---|---|
author | Yao, Jiaqi Miao, Yifan Zhang, Yumei Zhu, Lv Chen, Huan Wu, Xiajia Yang, Yue Dai, Xiaoyu Hu, Qian Wan, Meihua Tang, Wenfu |
author_facet | Yao, Jiaqi Miao, Yifan Zhang, Yumei Zhu, Lv Chen, Huan Wu, Xiajia Yang, Yue Dai, Xiaoyu Hu, Qian Wan, Meihua Tang, Wenfu |
author_sort | Yao, Jiaqi |
collection | PubMed |
description | Dao-Chi powder (DCP) has been widely used in the treatment of inflammatory diseases in the clinical practice of traditional Chinese medicine, but has not been used in acute pancreatitis (AP). This study aimed to evaluate the effect of DCP on severe AP (SAP) and SAP-associated intestinal and cardiac injuries. To this end, an SAP animal model was established by retrograde injection of 3.5% taurocholic acid sodium salt into the biliopancreatic ducts of rats. Intragastric DCP (9.6 g/kg.BW) was administered 12 h after modeling. The pancreas, duodenum, colon, heart and blood samples were collected 36 h after the operation for histological and biochemical detection. The tissue distributions of the DCP components were determined and compared between the sham and the SAP groups. Moreover, molecular docking analysis was employed to investigate the interactions between the potential active components of DCP and its targets (Nrf2, HO-1, and HMGB1). Consequently, DCP treatment decreased the serum levels of amylase and the markers of gastrointestinal and cardiac injury, further alleviating the pathological damage in the pancreas, duodenum, colon, and heart of rats with SAP. Mechanistically, DCP rebalanced the pro-/anti-inflammatory cytokines and inhibited MPO activity and MDA levels in these tissues. Furthermore, Western blot and RT-PCR results showed that DCP intervention enhanced the expression of Nrf2 and HO-1 in the duodenum and colon of rats with SAP, while inhibiting the expression of HMGB1 in the duodenum and heart. HPLC-MS/MS analysis revealed that SAP promoted the distribution of ajugol and oleanolic acid to the duodenum, whereas it inhibited the distribution of liquiritigenin to the heart and ajugol to the colon. Molecular docking analysis confirmed that the six screened components of DCP had relatively good binding affinity with Nrf2, HO-1, and HMGB1. Among these, oleanolic acid had the highest affinity for HO-1. Altogether, DCP could alleviated SAP-induced intestinal and cardiac injuries via inhibiting the inflammatory responses and oxidative stress partially through regulating the Nrf2/HO-1/HMGB1 signaling pathway, thereby providing additional supportive evidence for the clinical treatment of SAP. |
format | Online Article Text |
id | pubmed-9310041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93100412022-07-26 Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats Yao, Jiaqi Miao, Yifan Zhang, Yumei Zhu, Lv Chen, Huan Wu, Xiajia Yang, Yue Dai, Xiaoyu Hu, Qian Wan, Meihua Tang, Wenfu Front Pharmacol Pharmacology Dao-Chi powder (DCP) has been widely used in the treatment of inflammatory diseases in the clinical practice of traditional Chinese medicine, but has not been used in acute pancreatitis (AP). This study aimed to evaluate the effect of DCP on severe AP (SAP) and SAP-associated intestinal and cardiac injuries. To this end, an SAP animal model was established by retrograde injection of 3.5% taurocholic acid sodium salt into the biliopancreatic ducts of rats. Intragastric DCP (9.6 g/kg.BW) was administered 12 h after modeling. The pancreas, duodenum, colon, heart and blood samples were collected 36 h after the operation for histological and biochemical detection. The tissue distributions of the DCP components were determined and compared between the sham and the SAP groups. Moreover, molecular docking analysis was employed to investigate the interactions between the potential active components of DCP and its targets (Nrf2, HO-1, and HMGB1). Consequently, DCP treatment decreased the serum levels of amylase and the markers of gastrointestinal and cardiac injury, further alleviating the pathological damage in the pancreas, duodenum, colon, and heart of rats with SAP. Mechanistically, DCP rebalanced the pro-/anti-inflammatory cytokines and inhibited MPO activity and MDA levels in these tissues. Furthermore, Western blot and RT-PCR results showed that DCP intervention enhanced the expression of Nrf2 and HO-1 in the duodenum and colon of rats with SAP, while inhibiting the expression of HMGB1 in the duodenum and heart. HPLC-MS/MS analysis revealed that SAP promoted the distribution of ajugol and oleanolic acid to the duodenum, whereas it inhibited the distribution of liquiritigenin to the heart and ajugol to the colon. Molecular docking analysis confirmed that the six screened components of DCP had relatively good binding affinity with Nrf2, HO-1, and HMGB1. Among these, oleanolic acid had the highest affinity for HO-1. Altogether, DCP could alleviated SAP-induced intestinal and cardiac injuries via inhibiting the inflammatory responses and oxidative stress partially through regulating the Nrf2/HO-1/HMGB1 signaling pathway, thereby providing additional supportive evidence for the clinical treatment of SAP. Frontiers Media S.A. 2022-07-11 /pmc/articles/PMC9310041/ /pubmed/35899121 http://dx.doi.org/10.3389/fphar.2022.922130 Text en Copyright © 2022 Yao, Miao, Zhang, Zhu, Chen, Wu, Yang, Dai, Hu, Wan and Tang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yao, Jiaqi Miao, Yifan Zhang, Yumei Zhu, Lv Chen, Huan Wu, Xiajia Yang, Yue Dai, Xiaoyu Hu, Qian Wan, Meihua Tang, Wenfu Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title | Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title_full | Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title_fullStr | Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title_full_unstemmed | Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title_short | Dao-Chi Powder Ameliorates Pancreatitis-Induced Intestinal and Cardiac Injuries via Regulating the Nrf2-HO-1-HMGB1 Signaling Pathway in Rats |
title_sort | dao-chi powder ameliorates pancreatitis-induced intestinal and cardiac injuries via regulating the nrf2-ho-1-hmgb1 signaling pathway in rats |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310041/ https://www.ncbi.nlm.nih.gov/pubmed/35899121 http://dx.doi.org/10.3389/fphar.2022.922130 |
work_keys_str_mv | AT yaojiaqi daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT miaoyifan daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT zhangyumei daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT zhulv daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT chenhuan daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT wuxiajia daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT yangyue daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT daixiaoyu daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT huqian daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT wanmeihua daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats AT tangwenfu daochipowderamelioratespancreatitisinducedintestinalandcardiacinjuriesviaregulatingthenrf2ho1hmgb1signalingpathwayinrats |